Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ADR Biomedical Holdings's annualizedNet Income for the quarter that ended in Mar. 2026 was 円-531.56 Mil. ADR Biomedical Holdings's average total tangible assets for the quarter that ended in Mar. 2026 was 円485.00 Mil. Therefore, ADR Biomedical Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -109.60%.
The historical rank and industry rank for ADR Biomedical Holdings's Return-on-Tangible-Asset or its related term are showing as below:
TSE:3750'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -45.87 Med: -3.16 Max: 10.96
Current: -26.43
During the past 13 years, ADR Biomedical Holdings's highest Return-on-Tangible-Asset was 10.96%. The lowest was -45.87%. And the median was -3.16%.
TSE:3750's Return-on-Tangible-Asset is ranked better than 57.77% of 1416
companies
in the Biotechnology industry
Industry Median: -35.435
vs TSE:3750: -26.43
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ADR Biomedical Holdings Return-on-Tangible-Asset Related Terms
ADR Biomedical Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ADR Biomedical Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -109.60% mean?
ADR Biomedical Holdings (TSE:3750) has a Return-on-Tangible-Asset of -109.60% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ADR Biomedical Holdings and its competitors. According to the industry distribution chart, ADR Biomedical Holdings ranks #598 out of 1416 companies in the Biotechnology industry, placing it in the top 42.2%.
Is ADR Biomedical Holdings' Return-on-Tangible-Asset too high?
ADR Biomedical Holdings' current Return-on-Tangible-Asset is -109.60%. Based on the distribution chart, ADR Biomedical Holdings ranks #598 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ADR Biomedical Holdings has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #598 out of 1416 companies for Return-on-Tangible-Asset. This puts ADR Biomedical Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Return-on-Tangible-Asset is -109.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.81, compared to a current price of 円787.00 — trading 1876.9% above its estimated fair value. The current Return-on-Tangible-Asset is -109.60%. ADR Biomedical Holdings' overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Return-on-Tangible-Asset is -109.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円787.00 is trading 1876.9% above its estimated GF Value™ of 円39.81.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
Return-on-Tangible-Asset: -109.60%
GF Value™: 円39.81 vs. price of 円787.00 (1876.9% above fair value)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
28GF Score
Get the complete analysis for TSE:3750
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
